[{"id":"027ae0ad-75fc-4cbb-bdb2-326e57dba8b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT07042438","created_at":"2025-07-05T14:03:14.313Z","updated_at":"2025-07-05T14:03:14.313Z","phase":"Phase 2","brief_title":"Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells","source_id_and_acronym":"NCT07042438","lead_sponsor":"City of Hope Medical Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yescarta (axicabtagene ciloleucel)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 01/17/2026","start_date":" 01/17/2026","primary_txt":" Primary completion: 04/13/2028","primary_completion_date":" 04/13/2028","study_txt":" Completion: 04/13/2028","study_completion_date":" 04/13/2028","last_update_posted":"2025-06-29"},{"id":"c6520123-3091-4e6d-9609-b12e42d32d50","acronym":"","url":"https://clinicaltrials.gov/study/NCT04205838","created_at":"2024-05-08T20:28:52.767Z","updated_at":"2025-02-25T15:43:48.249Z","phase":"Phase 2","brief_title":"Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients with Recurrent or Refractory Large B-cell Lymphoma","source_id_and_acronym":"NCT04205838","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV • Kineret (anakinra)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-12-13"},{"id":"f5de46f2-d18a-4c9b-9824-b8d60d25c24c","acronym":"RG1006269","url":"https://clinicaltrials.gov/study/NCT04257578","created_at":"2021-01-18T20:41:36.655Z","updated_at":"2025-02-25T14:58:51.439Z","phase":"Phase 1/2","brief_title":"Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma","source_id_and_acronym":"NCT04257578 - RG1006269","lead_sponsor":"University of Washington","biomarkers":" CD4","pipe":" | ","alterations":" CD19 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib) • Yescarta (axicabtagene ciloleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/02/2020","start_date":" 12/02/2020","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2024-10-29"},{"id":"b7bc4ff3-bac9-4849-9ac4-4b756ff3134c","acronym":"ZUMA-24","url":"https://clinicaltrials.gov/study/NCT05459571","created_at":"2022-07-15T16:05:23.458Z","updated_at":"2024-07-02T16:34:25.986Z","phase":"Phase 2","brief_title":"Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma","source_id_and_acronym":"NCT05459571 - ZUMA-24","lead_sponsor":"Kite, A Gilead Company","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/09/2022","start_date":" 08/09/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-06-14"},{"id":"523cb57a-001f-4d73-8c81-664052823b24","acronym":"","url":"https://clinicaltrials.gov/study/NCT05757219","created_at":"2023-03-07T18:02:49.882Z","updated_at":"2024-07-02T16:34:38.016Z","phase":"Phase 2","brief_title":"Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy","source_id_and_acronym":"NCT05757219","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" JAK1 • CRP","pipe":"","alterations":" ","tags":["JAK1 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yescarta (axicabtagene ciloleucel) • itacitinib (INCB039110)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-06-05"},{"id":"97131464-120c-4497-92ac-88a2fa5c808a","acronym":"AMC-112","url":"https://clinicaltrials.gov/study/NCT05077527","created_at":"2021-10-14T19:57:31.317Z","updated_at":"2024-07-02T16:35:03.833Z","phase":"Phase 1","brief_title":"Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05077527 - AMC-112","lead_sponsor":"AIDS Malignancy Consortium","biomarkers":" CD4","pipe":" | ","alterations":" CD19 positive","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/20/2024","start_date":" 07/20/2024","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-05-14"},{"id":"81d99580-964a-4d43-9dfd-629d1f93a58c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03642626","created_at":"2021-01-18T17:52:54.288Z","updated_at":"2024-07-02T16:35:14.310Z","phase":"","brief_title":"MT2017-45: CAR-T Cell Therapy for Heme Malignancies","source_id_and_acronym":"NCT03642626","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Tecartus (brexucabtagene autoleucel) • Abecma (idecabtagene vicleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 12/18/2018","start_date":" 12/18/2018","primary_txt":" Primary completion: 02/09/2024","primary_completion_date":" 02/09/2024","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-03-18"},{"id":"28c2e848-0f11-4013-9ceb-12f7e4e707d8","acronym":"ZUMA-7","url":"https://clinicaltrials.gov/study/NCT03391466","created_at":"2021-01-18T16:44:14.245Z","updated_at":"2024-07-02T16:35:15.970Z","phase":"Phase 3","brief_title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT03391466 - ZUMA-7","lead_sponsor":"Kite, A Gilead Company","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD20 negative","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cytarabine • cyclophosphamide • oxaliplatin • Yescarta (axicabtagene ciloleucel) • fludarabine IV • methylprednisolone sodium succinate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 359","initiation":"Initiation: 01/25/2018","start_date":" 01/25/2018","primary_txt":" Primary completion: 03/18/2021","primary_completion_date":" 03/18/2021","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-03-07"},{"id":"48501323-09cb-4f5b-a243-32ead55180fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05370547","created_at":"2022-05-11T15:55:57.619Z","updated_at":"2024-07-02T16:35:16.239Z","phase":"Phase 1/2","brief_title":"Chidamide Bridging for CAR-T Therapy","source_id_and_acronym":"NCT05370547","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" BCL2 • BCL6 • PMAIP1","pipe":" | ","alterations":" CD19 positive","tags":["BCL2 • BCL6 • PMAIP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Epidaza (chidamide) • fludarabine IV • Carteyva (relmacabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-06"},{"id":"4e146a44-d064-44ac-94c6-9a5142727e36","acronym":"ZUMA-12","url":"https://clinicaltrials.gov/study/NCT03761056","created_at":"2022-07-08T22:54:07.243Z","updated_at":"2024-07-02T16:35:30.615Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma","source_id_and_acronym":"NCT03761056 - ZUMA-12","lead_sponsor":"Kite, A Gilead Company","biomarkers":" IFNG • IL6 • CXCL8 • GZMB • IL5 • CRP","pipe":"","alterations":" ","tags":["IFNG • IL6 • CXCL8 • GZMB • IL5 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 01/29/2019","start_date":" 01/29/2019","primary_txt":" Primary completion: 05/17/2021","primary_completion_date":" 05/17/2021","study_txt":" Completion: 10/12/2023","study_completion_date":" 10/12/2023","last_update_posted":"2023-11-02"},{"id":"cbb4a797-7cab-4ad4-a4e4-ada365aa9943","acronym":"HOVON161","url":"https://clinicaltrials.gov/study/NCT05641428","created_at":"2022-12-07T15:57:21.954Z","updated_at":"2024-07-02T16:35:59.515Z","phase":"Phase 2","brief_title":"Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL","source_id_and_acronym":"NCT05641428 - HOVON161","lead_sponsor":"University Medical Center Groningen","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yescarta (axicabtagene ciloleucel) • Qartemi (varnimcabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 10/18/2022","start_date":" 10/18/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2022-12-07"},{"id":"4608c564-d9e9-4ab5-91b3-70a26ad8628a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00924326","created_at":"2021-01-18T03:34:48.192Z","updated_at":"2024-07-02T16:36:18.533Z","phase":"Phase 1/2","brief_title":"CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma","source_id_and_acronym":"NCT00924326","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV • Proleukin (aldesleukin)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 02/17/2009","start_date":" 02/17/2009","primary_txt":" Primary completion: 09/30/2015","primary_completion_date":" 09/30/2015","study_txt":" Completion: 11/17/2021","study_completion_date":" 11/17/2021","last_update_posted":"2022-01-12"}]